Male SAS/4 mice were injected i.v. with 6.6 kBq 239Pu-citrate. After 1 or 24 h a single i.p. injection of 15 or 30 mumol kg-1 or repeated (three or four) daily
injections of 30 mumol kg-1 of
tetra-THB-spermine were given, and at 4 or 7 days Pu retention was measured in liver, kidneys and femur. Besides
tetra-THB-spermine, equimolar doses of
tetra-DHB-spermine were injected for comparison, or equimolar doses of
diethylene triamine-pentaacetic
acid (
DTPA) as a reference compound. Histological changes in kidneys and liver were examined after i.p.
injections of 30 mumol kg-1 or at 2-13 times higher doses of
tetra-THB-spermine. The results show that: (1) Introduction of an additional hydroxy group into the aromatic moieties of
tetra-DHB-spermine results in increased hydrophilicity, lower toxicity and a lower renal retention of Pu. (2)
Tetra-THB-spermine and
tetra-DHB-spermine are similarly effective in removing
plutonium from liver and bone. Their efficacies in removing Pu from bone are approximately similar to those of
DTPA but for whole-body removal they are generally inferior. (3) Multiple (30 mumol kg-1) of
tetra-THB-spermine were no more effective than a single injection at mobilizing Pu from the liver. (4) Four
injections of
tetra-THB-spermine induced cloudy swelling and fatty degeneration in epithelial cells of the proximal convoluted tubules. At levels of 400 mumol kg-1
tetra-THB-spermine produced severe degenerative glomerular lesions, foci of liver
necrosis and
thromboses of the portal vein branch.